Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Melanoma Approvals Break New Ground In Immunotherapy

Executive Summary

First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.

Advertisement

Related Content

New Melanoma Frontier Opens To Bristol's Opdivo And Novartis/Glaxo's BRAF/MEK Combo
Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race
Does Imlygic Make The Case For FDA Oncology Center Of Excellence?
Merck Points To Keytruda, Zepatier Promise Coming Off Lackluster Quarter
Bristol Offers Yervoy For Free In New Early Melanoma Indication
Amgen’s Imlygic Approval A Milestone For Oncolytic Cancer Vaccines
Creative Drug Pricing Hindered By Medicaid Best Price, Stakeholders Say
Bristol Hits Sweet Spot On Checkpoint Inhibitor Combination Pricing
Yervoy/Nivolumab May Need Stronger Survival Data To Be First Choice In Melanoma
Amgen Takes Out Cancer Vaccine Developer BioVex In Potential $1B Deal

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057245

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel